Somaxon Pharmaceuticals Inc

Somaxon Pharmaceuticals — BIO CEO & Investor Conference 2010

26 slides from Somaxon Pharmaceuticals's conference presentation, Feb 8, 2010

  1. Slide 1: Somaxon Pharmaceuticals, Inc. BIO CEO & Investor Conference

    Slide 1: Somaxon Pharmaceuticals, Inc. BIO CEO & Investor Conference

    Somaxon Pharmaceuticals, Inc. February 8, 2010 BIO CEO & Investor Conference Nasdaq: SOMX

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential regulatory approval for our product candidate, development timelines, future financial results and events that have not yet occurred. Pharmaceutica

  3. Slide 3: Somaxon: A Focus on CNS

    Slide 3: Somaxon: A Focus on CNS

    Somaxon: A Focus on CNS Specialty pharmaceutical company Core asset: Silenor for insomnia NDA under FDA review - Class 1 Resubmission FDA Action date: March 21, 2010 Partnering discussions ongoing NASDAQ: SOMX

  4. Slide 4: Focused Strategy Reduces Risk

    Slide 4: Focused Strategy Reduces Risk

    Focused Strategy Reduces Risk Develop and Commercialize Highly Differentiated Products Target late-stage or currently marketed assets Address unmet medical need and patient dissatisfaction Leverage development, regulatory and commercial expertise Deploy a U.S. Commercial Organization Focus on the CN

  5. Slide 5: Silenor for Insomnia Near-term Opportunity

    Slide 5: Silenor for Insomnia Near-term Opportunity

    Silenor for Insomnia Near-term Opportunity "Launch Ready" Marketing Campaign: 2H 2010 possible launch with partner Product profile supports attractive revenue estimates Changing insomnia market dynamics ? commercial upside Differentiated Mechanism of Action H1 specificity vs. GABA or melatonin Stron

  6. Slide 6: Pharmaceuticals

    Slide 6: Pharmaceuticals

    \\ a aS Pharmaceuticals

  7. Slide 7: U.S. Insomnia Market: Large and Dissatisfied

    Slide 7: U.S. Insomnia Market: Large and Dissatisfied

    U.S. Insomnia Market: Large and Dissatisfied 70 million people in the U.S. suffer from insomnia Market remains under-diagnosed, under-treated, and dissatisfied 14 million (20%) are currently on Rx treatment 9 million (67%) are not satisfied 56 million utilize OTC and other remedies Current options f

  8. Slide 8: Market Dissatisfied with Current Options

    Slide 8: Market Dissatisfied with Current Options

    Poorly/Not at All Controlled Completely/Well Controlled Somewhat Controlled 4th Qtr East 39 12 49 20.4 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 Market Dissatisfied with Current Options Somaxon Market Research, 2006; n = 451 "How well would you say your insomnia/sleep problem is controlled?"

  9. Slide 9: Room for Improvement

    Slide 9: Room for Improvement

    Room for Improvement Patients Not Satisfied With Rx GABA Products Less Time to Get to Sleep Woke Less During Night Slept Longer Felt Rested on Waking Felt Better Overall East 76.2 60.8 48.6 47 48.1 % of Patients Taking "Z Drugs"* <50% report sleeping longer, feeling rested, or feeling better overall

  10. Slide 10: Sleep Maintenance is Primary Issue

    Slide 10: Sleep Maintenance is Primary Issue

    Sleep Maintenance is Primary Issue 65% 35% Sleep Problem in Past Month At Least a Few Nights/Week 49% Woke Unrefreshed 42% Frequent Nocturnal Awakenings 29% Early Morning Awakenings 26% Difficulty Falling Asleep National Sleep Foundation. Summary of findings: 2008 Sleep in America poll. n = 1760 res

  11. Slide 11: Large and Accessible Market

    Slide 11: Large and Accessible Market

    Large and Accessible Market Over 70 million TRx's in the U.S. 2009 Demographics favorable for continued year over year growth Prescription growth accelerates with the introduction of novel, differentiated products Patients want new options 90% would be willing to try Silenor 70% would ask for it on

  12. Slide 12: Changing Market Dynamics Create Opportunities

    Slide 12: Changing Market Dynamics Create Opportunities

    Changing Market Dynamics Create Opportunities Solid "window of opportunity" for new treatments A void of new and differentiated insomnia treatments since 2006 No "novel" compounds expected to launch in near term Clinical and Regulatory setbacks for several drugs in development Somaxon estimates seve

  13. Slide 13: A Novel Treatment for Insomnia: Silenor

    Slide 13: A Novel Treatment for Insomnia: Silenor

    A Novel Treatment for Insomnia Silenor

  14. Slide 14: Starting With a Differentiated Mechanism of Action

    Slide 14: Starting With a Differentiated Mechanism of Action

    Starting With a Differentiated Mechanism of Action Histamine (H1) is one of several waking neuro-transmitters important in the arousal system Silenor has high affinity for H1 receptors Twenty-fold more potent than diphenhydramine, and significantly more selective Silenor has significant effects at n

  15. Slide 15: Finishing With a Strong Clinical Profile

    Slide 15: Finishing With a Strong Clinical Profile

    Finishing With a Strong Clinical Profile Six controlled clinical trials completed Adult and elderly populations Chronic and transient insomnia Primary efficacy endpoint achieved statistical significance in each of Phase 2 and 3 studies Comprehensive Phase 1/Non-clinical program completed Cardiac stu

  16. Slide 16: Silenor: Just What the Patient Ordered

    Slide 16: Silenor: Just What the Patient Ordered

    Silenor: Just What the Patient Ordered Treat sleep maintenance insomnia The most significant insomnia complaint 7-8 hours of sleep with Silenor Prevention of early morning awakenings - a full night's sleep Unique potential positioning for Silenor Sleep onset (<30 min) Clinically meaningful Proposed

  17. Slide 17: Silenor Commercialization

    Slide 17: Silenor Commercialization

    Silenor Commercialization Silenor

  18. Slide 18: A Refreshingly Different Sleep Solution

    Slide 18: A Refreshingly Different Sleep Solution

    A Refreshingly Different Sleep Solution Silenor Commercialization

  19. Slide 19: Silenor Branding Platform

    Slide 19: Silenor Branding Platform

    Silenor Branding Platform Brand Identity - Refreshingly Different Key Messages - A full 7-8 hours of sleep - Safe for chronic use - Non-addicting, no abuse potential - Placebo-like side effect profile - No residual hangover effect - Unique MOA Positioning - -Silenor is first-line therapy for sleep m

  20. Slide 20: "Plan to Win"

    Slide 20: "Plan to Win"

    "Plan to Win" Capitalize on the Changing Market Dynamics Competitor "turbulence" Lack of differentiated insomnia treatments Shift from expensive DTC strategy Launch with a Competitive Share of Voice with a Partner Target high value physicians Utilize non-personal promotional efforts to leverage into

  21. Slide 21: Somaxon Pharmaceuticals, Inc. Corporate Summary

    Slide 21: Somaxon Pharmaceuticals, Inc. Corporate Summary

    Somaxon Pharmaceuticals, Inc. Corporate Summary

  22. Slide 22: Strategic Collaboration for Silenor

    Slide 22: Strategic Collaboration for Silenor

    Strategic Collaboration for Silenor GOALS Successful Silenor launch in 2H 2010 Build a focused Somaxon commercial organization Maximize shareholder value Traditional licensing with co-promotion rights Co-promotion with shared revenues and costs M&A to gain access to sales infrastructure/ products

  23. Slide 23: Financials

    Slide 23: Financials

    Financials Cash, cash equivalents & marketable securities (12/31/09) Shares outstanding Fully diluted shares $5.2 MM* 23.1 MM 34.9 MM * Sufficient to fund operations through 2Q 2010 based upon current operating plan

  24. Slide 24: Near-Term Priorities

    Slide 24: Near-Term Priorities

    Near-Term Priorities Obtain regulatory approval for Silenor NDA re-submission accepted March 21, 2010 FDA action date Partner Silenor Ongoing dialogue with multiple parties Build commercial infrastructure Execute post-approval Launch Silenor in U.S. in 2H 2010

  25. Slide 25: Somaxon Value Proposition

    Slide 25: Somaxon Value Proposition

    Somaxon Value Proposition Silenor Highly differentiated insomnia treatment Favorable market dynamics "Launch Ready" campaign following regulatory approval Attractive revenue potential Experienced management team Significant commercial launch experience Building a focused commercial organization Capa

  26. Slide 26: Thank You!

    Slide 26: Thank You!

    Somaxon Pharmaceuticals, Inc. Thank You!

Source: SEC EDGAR · 8-K filed Feb 8, 2010

More decks from Somaxon Pharmaceuticals Inc